Symbols / VERU Stock $2.26 -0.44% Veru Inc.

Healthcare • Biotechnology • United States • NCM
VERU (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Mitchell S. Steiner F.A.C.S., M.D.
Exch · Country NCM · United States
Market Cap 36.27M
Enterprise Value 4.11M
Income -19.20M
Sales —
FCF (ttm) -11.04M
Book/sh 2.31
Cash/sh 2.20
Employees 20
Insider 10d —
IPO Feb 11, 1999
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.88
PEG 3.60
P/S —
P/B 0.98
P/C —
EV/EBITDA -0.14
EV/Sales —
Quick Ratio 4.95
Current Ratio 5.16
Debt/Eq 8.02
LT Debt/Eq —
EPS (ttm) -1.21
EPS next Y -1.20
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-02-11
ROA -42.92%
ROE -60.25%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 16.05M
Shs Float 13.48M
Insider Own 9.78%
Instit Own 23.84%
Short Float 3.99%
Short Ratio 10.86
Short Interest 577.16K
52W High 7.40
vs 52W High -69.46%
52W Low 2.06
vs 52W Low 9.71%
Beta -1.17
Impl. Vol. 5.83%
Rel Volume 0.97
Avg Volume 54.66K
Volume 52.90K
Target (mean) $25.00
Tgt Median $25.00
Tgt Low $25.00
Tgt High $25.00
# Analysts 2
Recom None
Prev Close $2.27
Price $2.26
Change -0.44%
About

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$25.00
Mean price target
2. Current target
$2.26
Latest analyst target
3. DCF / Fair value
$-12.38
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.26
Low
$25.00
High
$25.00
Mean
$25.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-12-18 init Canaccord Genuity — → Buy $25
2025-08-13 main Raymond James Outperform → Outperform $20
2025-01-02 reit HC Wainwright & Co. Buy → Buy $3
2024-12-20 reit HC Wainwright & Co. Buy → Buy $3
2024-11-05 reit Oppenheimer Outperform → Outperform $5
2024-05-14 init B. Riley Securities — → Buy $5
2024-05-13 reit HC Wainwright & Co. Buy → Buy $3
2024-05-06 main HC Wainwright & Co. Buy → Buy $3
2024-04-15 reit Oppenheimer Outperform → Outperform $5
2024-03-28 init Raymond James — → Outperform $3
2024-02-08 reit HC Wainwright & Co. Buy → Buy $2
2023-09-27 reit HC Wainwright & Co. Buy → Buy $2
2023-06-07 up Jefferies Underperform → Hold $1
2023-05-15 main HC Wainwright & Co. Buy → Buy $2
2023-05-08 reit HC Wainwright & Co. — → Buy $6
2023-04-12 reit HC Wainwright & Co. — → Buy $6
2023-04-06 main HC Wainwright & Co. — → Buy $6
2023-03-15 main Oppenheimer — → Outperform $9
2023-02-14 main Oppenheimer — → Outperform $14
2023-02-10 main HC Wainwright & Co. — → Buy $14
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-02-19 RANKOWITZ MICHAEL L Director — 150,000 $0.55 $84,351
2024-05-24 BARNETTE K GARY PH.D. Officer — 5,000 $1.34 $6,696
2024-05-24 FISCH HARRY Officer and Director — 4,000 $1.25 $5,000
2024-05-24 STEINER MITCHELL SHUSTER Chief Executive Officer — 70,183 $1.23 $87,525
2024-05-17 STEINER MITCHELL SHUSTER Chief Executive Officer — 171,875 $1.32 $246,929
2024-05-15 FISCH HARRY Officer and Director — 6,711 $1.49 $9,999
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Revenue
0.00
0.00
-100.00%
16.30
-58.59%
39.35
Operating Revenue
0.00
0.00
-100.00%
16.30
-58.59%
39.35
Cost Of Revenue
—
11.03
+26.36%
8.73
-0.36%
8.76
Reconciled Cost Of Revenue
—
11.03
+26.36%
8.73
-0.36%
8.76
Gross Profit
—
5.85
-22.63%
7.57
-75.27%
30.59
Operating Expense
35.53
-4.98%
37.39
-63.76%
103.17
-9.56%
114.08
Research And Development
15.59
+21.95%
12.78
-75.04%
51.20
-27.79%
70.91
Selling General And Administration
19.94
-18.96%
24.61
-48.79%
48.06
+11.30%
43.18
General And Administrative Expense
19.94
-18.96%
24.61
-48.79%
48.06
+11.33%
43.17
Other Gand A
19.94
-18.96%
24.61
-48.79%
48.06
+11.33%
43.17
Total Expenses
35.53
-4.98%
37.39
-66.59%
111.90
-8.91%
122.84
Operating Income
-35.53
+4.98%
-37.39
+60.89%
-95.61
-14.51%
-83.49
Total Operating Income As Reported
-24.75
+31.57%
-36.17
+61.43%
-93.78
-12.33%
-83.49
EBITDA
-35.38
+4.70%
-37.12
+58.74%
-89.98
-13.57%
-79.23
Normalized EBITDA
-54.46
-42.68%
-38.17
+59.72%
-94.76
-14.47%
-82.78
Reconciled Depreciation
0.15
-43.28%
0.27
-0.63%
0.27
+28.76%
0.21
EBIT
-35.53
+4.98%
-37.39
+58.57%
-90.25
-13.61%
-79.44
Total Unusual Items
19.08
+1722.77%
1.05
-78.13%
4.79
+34.57%
3.56
Total Unusual Items Excluding Goodwill
19.08
+1722.77%
1.05
-78.13%
4.79
+34.57%
3.56
Special Income Charges
19.41
+1486.80%
1.22
-32.94%
1.82
0.00
Other Special Charges
-8.62
—
—
—
Impairment Of Capital Assets
—
0.00
-100.00%
3.90
0.00
Net Income
-22.73
+39.88%
-37.80
+59.42%
-93.15
-10.84%
-84.04
Pretax Income
-15.68
+55.53%
-35.26
+61.95%
-92.67
-10.58%
-83.80
Net Non Operating Interest Income Expense
—
-0.61
+74.97%
-2.43
+44.45%
-4.37
Interest Expense Non Operating
—
0.61
-74.97%
2.43
-44.45%
4.37
Net Interest Income
—
-0.61
+74.97%
-2.43
+44.45%
-4.37
Interest Expense
—
0.61
-74.97%
2.43
-44.45%
4.37
Other Income Expense
19.85
+831.02%
2.13
-60.23%
5.36
+32.27%
4.05
Other Non Operating Income Expenses
0.77
-29.19%
1.09
+89.13%
0.57
+15.74%
0.50
Gain On Sale Of Security
-0.32
-83.88%
-0.18
-105.94%
2.96
-16.70%
3.56
Gain On Sale Of Business
—
—
—
0.00
Tax Provision
—
0.73
+51.00%
0.48
+103.14%
0.24
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
-100.00%
1.01
+34.57%
0.75
Net Income Including Noncontrolling Interests
-22.73
+39.88%
-37.80
+59.42%
-93.15
-10.84%
-84.04
Net Income From Continuing Operation Net Minority Interest
-15.68
+55.53%
-35.26
+62.15%
-93.15
-10.84%
-84.04
Net Income From Continuing And Discontinued Operation
-22.73
+39.88%
-37.80
+59.42%
-93.15
-10.84%
-84.04
Net Income Continuous Operations
-15.68
+55.53%
-35.26
+62.15%
-93.15
-10.84%
-84.04
Net Income Discontinuous Operations
-7.05
-177.20%
-2.54
—
—
Normalized Income
-34.76
+4.25%
-36.31
+62.54%
-96.93
-11.61%
-86.85
Net Income Common Stockholders
-22.73
+39.88%
-37.80
+59.42%
-93.15
-10.84%
-84.04
Diluted EPS
-1.55
+44.64%
-2.80
+74.55%
-11.00
-4.76%
-10.50
Basic EPS
-1.55
+44.64%
-2.80
+74.55%
-11.00
-4.76%
-10.50
Basic Average Shares
14.65
+8.59%
13.49
+58.73%
8.50
+6.05%
8.01
Diluted Average Shares
14.65
+8.59%
13.49
+58.73%
8.50
+6.05%
8.01
Diluted NI Availto Com Stockholders
-22.73
+39.88%
-37.80
+59.42%
-93.15
-10.84%
-84.04
Gain On Sale Of PPE
10.78
+781.53%
1.22
-78.63%
5.72
0.00
Provision For Doubtful Accounts
—
0.00
-100.00%
3.91
+46120.16%
-0.01
Total Other Finance Cost
—
—
—
—
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Assets
29.84
-50.62%
60.42
+20.78%
50.02
-63.04%
135.36
Current Assets
18.92
-46.30%
35.22
+53.59%
22.93
-77.95%
104.00
Cash Cash Equivalents And Short Term Investments
18.32
-28.60%
25.66
+166.57%
9.63
-88.00%
80.19
Cash And Cash Equivalents
15.79
-36.61%
24.92
+158.86%
9.63
-88.00%
80.19
Other Short Term Investments
2.53
+240.20%
0.74
—
—
Receivables
—
3.96
-12.12%
4.51
+26.91%
3.55
Accounts Receivable
—
3.96
-12.12%
4.51
+26.91%
3.55
Gross Accounts Receivable
—
7.90
-6.48%
8.45
+136.18%
3.58
Allowance For Doubtful Accounts Receivable
—
-3.94
+0.04%
-3.94
-15657.34%
-0.02
Inventory
—
4.14
-38.12%
6.70
-22.30%
8.62
Raw Materials
—
0.83
-55.38%
1.85
+11.55%
1.66
Work In Process
—
0.08
-29.80%
0.11
-87.07%
0.87
Finished Goods
—
4.82
-1.91%
4.91
-19.45%
6.10
Prepaid Assets
—
0.42
-58.32%
1.01
-89.60%
9.68
Assets Held For Sale Current
0.00
-100.00%
8.76
—
—
Other Current Assets
0.60
-26.11%
0.81
-26.62%
1.10
-44.11%
1.96
Total Non Current Assets
10.92
-56.66%
25.20
-6.99%
27.09
-13.61%
31.36
Net PPE
3.11
-16.64%
3.73
-37.65%
5.99
+0.21%
5.97
Gross PPE
3.71
-11.97%
4.22
-56.86%
9.77
+1.65%
9.61
Accumulated Depreciation
-0.60
-24.08%
-0.48
+87.22%
-3.79
-4.01%
-3.64
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.77
+0.00%
0.77
-47.96%
1.47
+2.18%
1.44
Other Properties
2.75
-15.52%
3.25
-55.72%
7.34
-4.54%
7.69
Leases
0.20
+0.00%
0.20
-79.23%
0.96
+98.30%
0.48
Goodwill And Other Intangible Assets
6.88
+0.00%
6.88
-0.09%
6.88
-36.58%
10.86
Goodwill
6.88
+0.00%
6.88
+0.00%
6.88
+0.00%
6.88
Other Intangible Assets
—
—
0.01
-99.85%
3.98
Non Current Deferred Assets
—
12.34
-2.89%
12.71
-1.99%
12.97
Non Current Deferred Taxes Assets
—
12.34
-2.89%
12.71
-1.99%
12.97
Other Non Current Assets
0.93
-93.62%
14.58
+864.36%
1.51
-3.15%
1.56
Total Liabilities Net Minority Interest
11.50
-59.07%
28.10
-7.39%
30.34
-42.27%
52.56
Current Liabilities
7.79
-34.40%
11.87
-33.37%
17.81
-53.99%
38.71
Payables And Accrued Expenses
3.52
+20.03%
2.93
-80.36%
14.92
-51.24%
30.60
Payables
3.12
+38.14%
2.26
-82.53%
12.93
-41.23%
22.00
Accounts Payable
3.12
+38.14%
2.26
-82.53%
12.93
-41.23%
22.00
Current Accrued Expenses
0.39
-41.09%
0.67
-66.31%
1.99
-76.87%
8.60
Pensionand Other Post Retirement Benefit Plans Current
3.51
-21.90%
4.49
+353.69%
0.99
-83.45%
5.99
Current Debt And Capital Lease Obligation
0.76
-56.95%
1.76
-7.28%
1.90
-10.58%
2.13
Current Debt
—
1.03
+18.65%
0.86
-26.04%
1.17
Other Current Borrowings
—
1.03
+18.65%
0.86
-26.04%
1.17
Current Capital Lease Obligation
0.76
+2.98%
0.74
-28.90%
1.04
+8.31%
0.96
Other Current Liabilities
—
2.68
—
—
Total Non Current Liabilities Net Minority Interest
3.72
-77.10%
16.23
+29.52%
12.53
-9.50%
13.85
Liabilities Heldfor Sale Non Current
0.00
-100.00%
0.02
—
—
Long Term Debt And Capital Lease Obligation
2.36
-79.94%
11.76
-5.98%
12.50
-9.06%
13.75
Long Term Debt
—
8.85
-0.22%
8.87
-8.14%
9.66
Long Term Capital Lease Obligation
2.36
-18.84%
2.91
-20.05%
3.63
-11.23%
4.09
Non Current Deferred Liabilities
—
—
0.00
-100.00%
0.08
Non Current Deferred Taxes Liabilities
—
—
0.00
-100.00%
0.08
Other Non Current Liabilities
1.36
-69.52%
4.46
+14798.89%
0.03
+61.21%
0.02
Stockholders Equity
18.33
-43.27%
32.32
+64.23%
19.68
-76.23%
82.80
Common Stock Equity
18.33
-43.27%
32.32
+64.23%
19.68
-76.23%
82.80
Capital Stock
0.15
+0.08%
0.15
-84.19%
0.94
+13.63%
0.83
Common Stock
0.15
+0.08%
0.15
-84.19%
0.94
+13.63%
0.83
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
14.87
+0.08%
14.86
+58.11%
9.40
+13.63%
8.27
Ordinary Shares Number
14.65
+0.08%
14.64
+59.49%
9.18
+14.00%
8.05
Treasury Shares Number
0.22
+0.00%
0.22
+0.00%
0.22
+0.00%
0.22
Additional Paid In Capital
343.29
+2.44%
335.13
+18.05%
283.89
+11.78%
253.97
Retained Earnings
-317.30
-7.72%
-294.57
-14.72%
-256.77
-56.93%
-163.62
Gains Losses Not Affecting Retained Earnings
0.00
+100.00%
-0.58
+0.00%
-0.58
+0.00%
-0.58
Treasury Stock
7.81
+0.00%
7.81
+0.00%
7.81
+0.00%
7.81
Other Equity Adjustments
—
-0.58
+0.00%
-0.58
+0.00%
-0.58
Total Equity Gross Minority Interest
18.33
-43.27%
32.32
+64.23%
19.68
-76.23%
82.80
Total Capitalization
18.33
-55.47%
41.17
+44.20%
28.55
-69.12%
92.45
Working Capital
11.13
-52.34%
23.36
+355.94%
5.12
-92.15%
65.29
Invested Capital
18.33
-56.55%
42.19
+43.45%
29.41
-68.58%
93.62
Total Debt
3.12
-76.94%
13.52
-6.15%
14.41
-9.26%
15.88
Net Debt
—
—
0.11
—
Capital Lease Obligations
3.12
-14.42%
3.64
-22.02%
4.67
-7.52%
5.05
Net Tangible Assets
11.45
-54.97%
25.44
+98.84%
12.79
-82.22%
71.94
Tangible Book Value
11.45
-54.97%
25.44
+98.84%
12.79
-82.22%
71.94
Inventories Adjustments Allowances
—
-1.58
-760.73%
-0.18
-1070.10%
-0.02
Notes Receivable
—
—
—
0.00
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Operating Cash Flow
-30.04
-38.56%
-21.68
+75.36%
-88.01
-85.27%
-47.51
Cash Flow From Continuing Operating Activities
-30.04
-38.56%
-21.68
+75.36%
-88.01
-85.27%
-47.51
Net Income From Continuing Operations
-22.73
+39.88%
-37.80
+59.42%
-93.15
-10.84%
-84.04
Depreciation Amortization Depletion
0.15
-43.28%
0.27
-0.63%
0.27
+28.76%
0.21
Depreciation And Amortization
0.15
-43.28%
0.27
-0.63%
0.27
+28.76%
0.21
Other Non Cash Items
0.47
-29.97%
0.67
-74.23%
2.61
+11.48%
2.34
Stock Based Compensation
8.10
-40.62%
13.64
-23.85%
17.92
+59.38%
11.24
Provisionand Write Offof Assets
-0.07
-104.65%
1.57
-61.76%
4.10
+5473.00%
0.07
Asset Impairment Charge
—
0.00
-100.00%
3.90
0.00
Deferred Tax
-0.00
-100.52%
0.37
+106.86%
0.18
+132.92%
0.08
Deferred Income Tax
-0.00
-100.52%
0.37
+106.86%
0.18
+132.92%
0.08
Operating Gains Losses
-12.16
-1421.05%
-0.80
+90.79%
-8.69
-144.20%
-3.56
Gain Loss On Investment Securities
3.14
+1213.10%
0.24
+108.07%
-2.96
+16.70%
-3.56
Unrealized Gain Loss On Investment Securities
0.32
+83.88%
0.18
0.00
—
Gain Loss On Sale Of PPE
0.00
-100.00%
0.18
+63440.34%
0.00
—
Change In Working Capital
-4.13
-1955.74%
0.22
+101.47%
-15.15
-157.95%
26.15
Change In Receivables
-0.66
-220.33%
0.55
+113.15%
-4.15
-191.53%
4.54
Changes In Account Receivables
-0.66
-220.33%
0.55
+113.15%
-4.15
-191.53%
4.54
Change In Inventory
0.86
-12.39%
0.99
+52.03%
0.65
+120.74%
-3.13
Change In Prepaid Assets
0.40
-53.88%
0.86
-91.21%
9.81
+718.95%
-1.58
Change In Payables And Accrued Expense
-4.11
-176.06%
-1.49
+92.84%
-20.79
-177.61%
26.79
Change In Accrued Expense
-1.35
-134.16%
3.94
+133.66%
-11.72
-242.98%
8.20
Change In Payable
-2.76
+49.19%
-5.43
+40.12%
-9.07
-148.79%
18.59
Change In Account Payable
-2.76
+49.19%
-5.43
+40.12%
-9.07
-148.79%
18.59
Change In Other Current Liabilities
-0.63
+8.55%
-0.68
-2.54%
-0.67
-42.33%
-0.47
Investing Cash Flow
25.14
+17096.01%
0.15
-97.69%
6.33
+48.45%
4.27
Cash Flow From Continuing Investing Activities
25.14
+17096.01%
0.15
-97.69%
6.33
+48.45%
4.27
Capital Expenditure
-0.00
+99.32%
-0.16
+76.22%
-0.67
+9.19%
-0.73
Capital Expenditure Reported
-0.00
+99.32%
-0.16
+76.22%
-0.67
+9.19%
-0.73
Net Investment Purchase And Sale
0.39
0.00
—
—
Sale Of Investment
0.39
0.00
—
—
Net Business Purchase And Sale
16.47
0.00
0.00
-100.00%
5.00
Gain Loss On Sale Of Business
4.10
0.00
—
0.00
Net Other Investing Changes
8.28
+2618.99%
0.30
-95.65%
7.00
—
Financing Cash Flow
-4.22
-111.46%
36.83
+231.35%
11.11
+939.50%
1.07
Cash Flow From Continuing Financing Activities
-4.22
-111.46%
36.83
+231.35%
11.11
+939.50%
1.07
Net Issuance Payments Of Debt
—
—
0.00
+100.00%
-0.01
Repayment Of Debt
—
—
0.00
+100.00%
-0.01
Long Term Debt Payments
—
—
0.00
+100.00%
-0.01
Net Long Term Debt Issuance
—
—
0.00
+100.00%
-0.01
Net Common Stock Issuance
0.00
-100.00%
35.30
+487.34%
6.01
0.00
Proceeds From Stock Option Exercised
0.00
-100.00%
1.66
-68.20%
5.24
+385.56%
1.08
Net Other Financing Charges
-4.22
-3074.74%
-0.13
-1.68%
-0.13
—
Changes In Cash
-9.12
-159.66%
15.29
+121.67%
-70.57
-67.34%
-42.17
Beginning Cash Position
24.92
+158.86%
9.63
-88.00%
80.19
-34.46%
122.36
End Cash Position
15.79
-36.61%
24.92
+158.86%
9.63
-88.00%
80.19
Free Cash Flow
-30.04
-37.56%
-21.84
+75.37%
-88.68
-83.84%
-48.24
Interest Paid Supplemental Data
0.33
-52.76%
0.70
+27.00%
0.55
-78.83%
2.62
Income Tax Paid Supplemental Data
0.08
-78.70%
0.37
+49.10%
0.25
-41.40%
0.42
Common Stock Issuance
0.00
-100.00%
35.30
+487.34%
6.01
0.00
Issuance Of Capital Stock
0.00
-100.00%
35.30
+487.34%
6.01
0.00
Sale Of Business
16.47
0.00
0.00
-100.00%
5.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category